

# **GREENLEAF HEALTH**

## **CELL & GENE THERAPY CAPABILITIES**

**OUR EXPERIENCE.**  
**YOUR SUCCESS.**

Greenleaf Health is a leading FDA regulatory consulting firm guiding companies through the changing FDA landscape.

# ABOUT GREENLEAF HEALTH

**250+ YEARS**  
OF COMBINED FDA EXPERIENCE



## WHY GREENLEAF

Founded in 2007, Greenleaf Health is a leading FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies researching, developing, and manufacturing innovative solutions to pressing global public health challenges.

Greenleaf's robust blend of technical skill and FDA institutional knowledge enables the firm to provide reliable, objective guidance to companies developing medical products for the U.S. market.

## UNMATCHED EXPERTISE

Greenleaf's team brings unmatched expertise that companies need when navigating today's evolving FDA regulatory environment. The firm includes former leaders and regulatory professionals from the FDA, Capitol Hill, top global pharmaceutical and medical device companies, leading law firms, and the U.S. biotechnology trade organization.

Greenleaf experts draw on a combined total of more than 250 years of FDA experience and a network of technical specialists. This wealth of experience informs Greenleaf's understanding of the broad life sciences industry and allows us to deliver valuable insight throughout the product lifecycle.

# COMPREHENSIVE SERVICES



## PRODUCT QUALITY, MANUFACTURING & COMPLIANCE

Greenleaf experts identify and promote practices and procedures that will align a client's approach with the FDA's quality, safety, and compliance expectations.



## COMPLIANCE AUDIT, TRAINING & REMIEDIATION

Greenleaf works with a network of independent technical experts who provide comprehensive on-site compliance assessments, remediation, and inspection readiness.



## DRUG & BIOLOGICAL PRODUCTS

Greenleaf serves as a trusted regulatory partner, advising companies on the complex process of bringing new therapeutics to market in today's evolving FDA environment.



## MEDICAL DEVICE & COMBINATION PRODUCTS

Greenleaf applies extensive regulatory expertise to guide medical device clients from early-stage development to marketing authorization and throughout the product lifecycle.



## CELL & GENE THERAPY

Greenleaf assists sponsors of cell and gene therapies by optimizing FDA interactions and submissions to support development, manufacturing, quality, and regulatory review.



## REAL-WORLD EVIDENCE (RWE)

Greenleaf Health and Trio Health have united to provide a cutting-edge combination of technology and regulatory insight via Trio's groundbreaking real-world evidence technology platform.



## ADVISORY SERVICES

Greenleaf understands the complex environment within which life sciences transactions take place and performs in-depth regulatory risk assessments tailored to investors' needs.




## LITIGATION SUPPORT

Greenleaf works closely with litigators representing FDA-regulated clients in a wide array of disputes related to medical devices and product quality, manufacturing, and compliance.

# CELL & GENE THERAPY TEAM


---

Experts from Greenleaf's Cell and Gene Therapy Team demonstrate unmatched levels of skill in their specialties of drug and biological products and product quality, manufacturing, and compliance. Led by Karen Midthun, M.D., and John Taylor, the team is guided by decades of regulatory experience in senior FDA positions, global public health organizations, academia, and industry.



**KAREN MIDTHUN, M.D.**  
Principal, Drug & Biological Products

An infectious disease physician by training, with a 28-year career in public service, including as Director of the FDA's Center for Biologics.



**JOHN JENKINS, M.D.**  
Principal, Drug & Biological Products

Former Director of the Office of New Drugs within the FDA's Center for Drugs.



**BOB MEYER, M.D.**  
Principal, Drug & Biological Products

A leader in drug and biological product lifecycle management with over 25 years of regulatory and academic leadership.



**KALAH AUCHINCLOSS**  
Senior Vice President,  
Regulatory Compliance

15 years of experience on Capitol Hill, in the private sector, and at the FDA, including role as Deputy Chief of Staff.



**JOHN TAYLOR**  
President  
Principal, Compliance & Regulatory Affairs

Former FDA senior official held many high-profile positions at the Agency, as well as senior leadership roles within industry.



**CYNTHIA SCHNEDAR**  
Executive Vice President,  
Regulatory Compliance

25-year compliance career, including serving as director of the FDA's drug compliance office.



**DAVID ELDER**  
Executive Vice President,  
Regulatory Compliance

23-year veteran of the FDA with prominent roles in domestic and foreign inspections, recalls and emergencies, and compliance actions.





# CELL & GENE THERAPY SERVICES

Greenleaf's cell and gene therapy services support companies striving to introduce new products to patients. The firm's team of experts has a robust blend of technical skill and FDA institutional knowledge that spans all therapeutic areas and quality, manufacturing, and compliance systems. By working cross-functionally, Greenleaf ensures that clients have the comprehensive, specialized guidance needed to understand and navigate the complex regulatory landscape for cell and gene therapies.



## PRODUCT DEVELOPMENT & REVIEW

Greenleaf's team specializes in strategic communications with the FDA at every stage of product development – early INTERACT meetings, pre-IND and meetings throughout development, correspondence, clinical trial design, submissions, FDA review communications and labeling discussions, and postmarket requirements.



## MANUFACTURING & QUALITY CONTROLS

Greenleaf experts provide strategic and technical support for establishing manufacturing and quality controls; pre- and postapproval inspection readiness; compliance assessments; evaluating and responding to FDA regulatory correspondence; and engaging with CBER's Advanced Technologies Team.



## REGULATORY LANDSCAPE

Greenleaf experts monitor and analyze the regulatory environment for emerging trends in cell and gene therapy regulation – including orphan drug designation and exclusivity, long-term follow-up requirements, companion diagnostics, the development and use of real-world evidence, and other agency policies and actions that could potentially impact current development programs – as well as changes to the competitive landscape for cell and gene therapies.



# QUALITY & COMPLIANCE SERVICES

Greenleaf offers an enhanced portfolio of services that includes comprehensive on-site compliance assessments, remediation, and inspection readiness, in addition to the firm's core regulatory consulting capabilities.



## COMPLIANCE ASSESSMENTS

Greenleaf works with life science entities to evaluate and strengthen compliance functions with an eye toward optimizing processes, mitigating risks, and creating a culture of compliance, while continuing to meet business objectives.



## FDA COMMUNICATIONS

Greenleaf's best-in-class experts bring value to any communication with the FDA, including formal regulatory communication, in-person meetings, and responses to compliance actions and regulatory correspondence.



## COMPLIANCE REMEDIATION

Greenleaf experts bring an unmatched level of credibility and trust when interacting with the FDA. The team has the experience and insight to successfully guide companies along the remediation pathway.



## CONSULTATION, TRAINING & REGULATORY GUIDANCE

Greenleaf delivers insight and guidance that help clients achieve business and regulatory objectives. The team also develops and delivers training on a variety of regulatory subjects.




## INSPECTION READINESS

Greenleaf experts strengthen clients' readiness for FDA preapproval and surveillance inspections through consulting, training, audits, and mock inspections.



## GCP SERVICES

Greenleaf specialists use a risk-based methodology to develop and improve clinical quality systems. Because there is no one-size-fits-all approach to GCP compliance, each solution is built to fit the targeted needs of the client.



## SUPPLY CHAIN OPTIMIZATION

Greenleaf uses a systemic approach to help clients strengthen and safeguard the integrity of their supply chain management practices and comply with the regulatory requirements of the Drug Supply Chain Security Act.




## CELL & GENE THERAPY

Greenleaf helps sponsors establish manufacturing and quality controls and engage with the FDA to address potential technical and regulatory challenges related to emerging manufacturing technologies.



# DRUG & BIOLOGICAL PRODUCTS SERVICES

Greenleaf's Drug and Biological Products Team specializes in providing strategic and technical guidance on medical product development, regulatory review, and postmarket requirements, working closely with clients to navigate today's evolving FDA regulatory environment.



## UNMATCHED REGULATORY EXPERIENCE

Greenleaf serves as a trusted regulatory partner, advising clients on the complex process of bringing new therapies to market. The team's multidisciplinary expertise helps companies evaluating and prioritizing their drug development pipeline to understand and effectively manage regulatory risk.



## PREMARKET REVIEW PROCESS

Greenleaf's team of experts provides strategic and technical consultation on: scientific and regulatory practices for clinical programs and regulatory submissions; identification of and eligibility for special designations, such as breakthrough therapy designation, RMAT, fast track, and accelerated approval; and preparation for FDA milestone meetings, such as EOP2, pre-filing meetings, mid-cycle review, and end-of-review meetings.



## CELL & GENE THERAPY

The Drug and Biological Products Team assists sponsors of cell and gene therapies with FDA interactions and submissions — including early INTERACT and pre-IND meetings; requests for orphan drug, RMAT, and rare pediatric disease designations; and data comparability questions — and helps to clarify FDA requirements for specific types of cellular products. The team also provides guidance on how to maximize clinical trial design for cell and gene therapies to treat rare and ultra-rare diseases.



## REAL-WORLD EVIDENCE (RWE)

Greenleaf's exclusive agreement with Trio Health, a leading provider of real-time data on real-world patients, gives clients the advantage of Trio's groundbreaking Multi-Disease Platform (MDX) integrated with Greenleaf's unrivaled regulatory knowledge. Greenleaf's team of experts provides end-to-end guidance to companies utilizing MDX data on how to optimize and validate the information to drive effective regulatory strategies.



# ADVISORY SERVICES





# ADVISORY SERVICES TEAM

Greenleaf’s team of advisors offers a rare blend of perspectives developed as leaders in both the public and private sectors. This wealth of experience informs Greenleaf’s understanding of the broad life sciences industry and enables us to deliver valuable insight throughout the product lifecycle.



**BRIAN CORRIGAN**  
SVP, Regulatory Policy

More than a decade of experience in the biopharmaceutical industry provides in-depth understanding of the U.S. health care system.



**JOHN TAYLOR**  
President and Principal,  
Compliance & Regulatory Affairs

Former FDA senior official held many high-profile positions at the Agency, as well as leadership roles within industry.



**JOHN JENKINS, M.D.**  
Principal, Drug &  
Biological Products

Former Director of the Office of New Drugs within the FDA’s Center for Drug Evaluation and Research (CDER).



**BOB MEYER, M.D.**  
Principal, Drug & Biological Products

A leader in drug and biological product lifecycle management with over 25 years of regulatory and academic leadership.



**KAREN MIDTHUN, M.D.**  
Principal, Drug & Biological Products

28-year career in public service, including as Director of the FDA’s Center for Biologics Evaluation and Research (CBER).



**DANIEL SCHULTZ, M.D.**  
Principal, Medical Device  
& Combination Products

35-year career includes service as Director of the FDA’s Center for Devices and Radiological Health (CDRH).



**PATRICK RONAN**  
Chief Executive Officer

25+ years of leadership experience that includes positions on Capitol Hill, at a leading global pharmaceutical company, and at the FDA, serving as a principal advisor to a number of FDA commissioners.



**MAURA NORDEN**  
SVP, Medical Device &  
Combination Products

15 years of experience advising FDA-regulated entities, investors, and public health organizations on a broad range of FDA regulatory matters.



**DAVID ELDER**  
EVP, Regulatory Compliance

23-year veteran of the FDA with prominent roles in global inspections, emergencies, and compliance actions.



# ADVISORY SERVICES

---

Greenleaf's in-depth knowledge and understanding of the FDA equips clients with a trusted partner when considering life sciences transactions. Greenleaf's advisory services are more than a compilation of public data. Greenleaf goes a step further by using the firm's vast institutional knowledge to provide in-depth analyses tailored to our clients' specific needs.

The firm's multidisciplinary team uses its extensive expertise to perform risk assessments that take into account business objectives, transaction timelines, and the industry landscape. The end result is an unbiased analysis identifying a target company's key regulatory risks, likelihood of the risks materializing, potential impact on the business, and opportunities to manage and mitigate risks in order to achieve desired regulatory outcomes. Greenleaf's comprehensive due diligence services evaluate a company's pipeline, or a specific asset, in the following areas:



## PRODUCT DEVELOPMENT & REVIEW

Analysis of the target company's regulatory filings and product development plans, including approvals and clearances, special designations, advisory committee decisions, labeling review, and investigational products.



## QUALITY MANUFACTURING

Assessment of the target company's manufacturing practices, compliance with quality system regulations (QSRs), good manufacturing practices (GMPs), and identification of inconsistencies that may affect the regulatory risk of a product or the company.



## IDENTIFICATION OF REGULATORY RISK

Evaluation of the target company's compliance with FDA regulations and identification of issues that may require attention and resources for remediation.

**OUR EXPERIENCE.**  
**YOUR SUCCESS.**